|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
|
3
|
Couraud S, Zalcman G, Milleron B, Morin F
and Souquet PJ: Lung cancer in never smokers - a review. Eur J
Cancer. 48:1299–1311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun S, Schiller JH and Gazdar AF: Lung
cancer in never smokers - a different disease. Nat Rev Cancer.
7:778–790. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Toh CK, Gao F, Lim WT, et al:
Never-smokers with lung cancer: epidemiologic evidence of a
distinct disease entity. J Clin Oncol. 24:2245–2251. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu X, Zhou R, Zhang Q, et al:
Identification and characterization of LAPTM4B encoded by a human
hepatocellular carcinoma-associated novel gene. Beijing Da Xue Xue
Bao. 35:340–347. 2003.(In Chinese).
|
|
7
|
Shao GZ, Zhou RL, Zhang QY, et al:
Molecular cloning and characterization of LAPTM4B, a novel
gene upregulated in hepatocellular carcinoma. Oncogene.
22:5060–5069. 2003.PubMed/NCBI
|
|
8
|
Zhang G, Liang Y, Huang Y, Chen Y and Zhou
R: Elevated lysosome-associated protein transmembrane-4β-35 is an
independent prognostic marker in pancreatic carcinoma. J Int Med
Res. 40:1275–1283. 2012.PubMed/NCBI
|
|
9
|
Zhou L, He XD, Chen J, et al:
Overexpression of LAPTM4B-35 closely correlated with
clinicopathological features and post-resectional survival of
gallbladder carcinoma. Eur J Cancer. 43:809–815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Y, Yang H, McNutt MA, et al: LAPTM4B
overexpression is an independent prognostic marker in ovarian
carcinoma. Oncol Rep. 20:1077–1083. 2008.PubMed/NCBI
|
|
11
|
Meng F, Luo C, Hu Y, et al: Overexpression
of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int
J Gynecol Pathol. 29:587–593. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang S, Zhang QY and Zhou RL: Relationship
between LAPTM4B gene polymorphism and susceptibility of
primary liver cancer. Ann Oncol. 23:1864–1869. 2012.
|
|
13
|
Liu Y, Zhang QY, Qian N and Zhou RL:
Relationship between LAPTM4B gene polymorphism and
susceptibility of gastric cancer. Ann Oncol. 18:311–316. 2007.
|
|
14
|
Cheng XJ, Xu W, Zhang QY and Zhou RL:
Relationship between LAPTM4B gene polymorphism and
susceptibility of colorectal and esophageal cancers. Ann Oncol.
19:527–532. 2008.
|
|
15
|
Yang H, Zhai G, Ji X, Xiong F, Su J and
McNutt MA: Correlation of LAPTM4B polymorphisms with gallbladder
carcinoma susceptibility in Chinese patients. Med Oncol.
29:2809–2813. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu Y, Liu Y, Zhou R, et al: LAPTM4B
polymorphisms is associated with ovarian cancer susceptibility and
its prognosis. Jpn J Clin Oncol. 42:413–419. 2012. View Article : Google Scholar
|
|
17
|
Li X, Kong X, Chen X, et al: LAPTM4B
allele *2 is associated with breast cancer susceptibility and
prognosis. PLoS One. 7:e449162012.
|
|
18
|
Deng LJ, Zhang QY, Liu B and Zhou RL:
Relationship between LAPTM4B gene polymorphism and
susceptibility of lung cancer. Beijing Da Xue Xue Bao. 37:302–305.
2005.(In Chinese).
|
|
19
|
Li C, Zhou Q, Wang Y, Chen X, Yang X and
Zhu D: Relationship between LAPTM4B gene polymorphism and
susceptibility of lung cancer. Zhongguo Fei Ai Za Zhi. 9:109–112.
2006.(In Chinese).
|
|
20
|
Zhai G, Yan K, Ji X, et al: LAPTM4B allele
*2 is a marker of poor prognosis for gallbladder carcinoma. PLoS
One. 7:e452902012.
|
|
21
|
Yang H, Zhai G, Ji X, Xiong F, Su J and
McNutt MA: LAPTM4B allele *2 is a marker of poor prognosis
following hepatic tumor resection for hepatocellular carcinoma.
PLoS One. 7:e349842012.
|
|
22
|
Meng F, Li H, Zhou R, Luo C, Hu Y and Lou
G: LAPTM4B gene polymorphism and endometrial carcinoma risk
and prognosis. Biomarkers. 18:136–143. 2013. View Article : Google Scholar
|
|
23
|
Sobin LGM and Wittekind C: TNM
Classification of Malignant Tumours. 7th edition. Wiley-Blackwell;
New York: 2010
|
|
24
|
Kasper G, Vogel A, Klaman I, et al: The
human LAPTM4b transcript is upregulated in various types of solid
tumours and seems to play a dual functional role during tumour
progression. Cancer Lett. 224:93–103. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiao M, Jia S, Wang H, Wang J, Huang Y and
Li Z: Overexpression of LAPTM4B: an independent prognostic
marker in breast cancer. J Cancer Res Clin Oncol. 139:661–667.
2013.
|
|
26
|
Kang Y, Yin M, Jiang W, et al:
Overexpression of LAPTM4B-35 is associated with poor prognosis in
colorectal carcinoma. Am J Surg. 204:677–683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yin M, Lou C, Zhang W, et al: LAPTM4B
overexpression is a novel independent prognostic marker for
metastatic ovarian tumors. Int J Gynecol Cancer. 22:54–62. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu X, Xiong F, Wei X, Yang H and Zhou R:
LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif
play critical roles in proliferation and metastatic potential of
hepatocellular carcinoma cells. Cancer Sci. 100:2335–2340. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang H, Xiong F, Wei X, Yang Y, McNutt MA
and Zhou R: Overexpression of LAPTM4B-35 promotes growth and
metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer
Lett. 294:236–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou L, He XD, Yu JC, Zhou RL, Shan Y and
Rui JA: Overexpression of LAPTM4B-35 attenuates epirubucin-induced
apoptosis of gallbladder carcinoma GBC-SD cells. Surgery.
150:25–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li L, Wei XH, Pan YP, et al: LAPTM4B: a
novel cancer-associated gene motivates multidrug resistance through
efflux and activating PI3K/AKT signaling. Oncogene. 29:5785–5795.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang M, Xu JJ, Zhou RL and Zhang QY: cAMP
responsive element binding protein-1 is a transcription factor of
lysosomal-associated protein transmembrane-4 beta in human breast
cancer cells. PLoS One. 8:e575202013. View Article : Google Scholar
|
